Ascending role of next-generation ALK inhibitors
Mené dans 20 pays sur 231 patients atteints d'un cancer du poumon non à petites cellules avec réarrangements ALK de stade IIIB ou IV, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du céritinib et d'une chimiothérapie, après l'échec d'un traitement à base de crizotinib et d'une ou de deux chimiothérapies à base de sels de platine
Anaplastic lymphoma kinase (ALK) gene rearrangements were first discovered in 5% of lung adenocarcinomas in 2007,1 and since then, these lung tumours have prompted a decade of breakneck development of precision oncology-based oral inhibitors. The first ALK tyrosine kinase inhibitor (TKI) approved by the US Food and Drug Administration (FDA) was crizotinib1 in August, 2011, and this TKI was confirmed in 2014 as the evidence-based first-line therapy,2 ousting platinum doublets. At the same time that crizotinib cemented its status as the initial anticancer palliative therapy for advanced ALK-rearranged lung cancer, more potent second-generation ALK TKIs than crizotinib moved rapidly through initial clinical trials into the oncologist's armamentarium.
The Lancet Oncology , commentaire, 2016